Dr. Lauren Weinand

The development and outcomes of prostate cancer can be significantly affected by multiple factors, such as genetic, socioeconomic, and environmental factors. Given this multifactorial approach to prostate cancer, disaggregating the available data on racial and ethnic subgroups is vital to pinpoint disparities in treatment status and diagnosis. In particular, Hispanic subpopulations with metastatic prostate cancer...

A lack of access to health care and treatment, brought about by socioeconomic and environmental factors, can impact the observed racial disparities in prostate cancer. While clinical trials open the doors to novel therapeutics targeted toward improving the survival of men with prostate cancer, an underrepresentation of racial groups could mean decreased insights into potential...

Multiple myeloma can affect different racial groups in different ways, especially since clinical trials are often skewed without equal representation. For example, around 20% of people affected by multiple myeloma are Black, but only 6% of participants in multiple myeloma clinical trials are Black.  This study, published in the Journal of Clinical Oncology for the 2022 ASCO...

As of 2021, breast cancer was the most common cancer around the globe. It is estimated that around 1 in 8 American women will be affected by breast cancer at some point in their lives. The prognosis for breast cancer is generally favorable if caught early, with a 5-year survival rate of around 90%. However,...

Photo by © ASCO/Todd Buchanan 2022. Written and edited by Lauren Weinand, M.D.  Equity: Every Day. Every Patient. Everywhere. That was the theme of last year’s ASCO annual meeting. The 2022 ASCO Annual Meeting theme—advancing equitable care through innovation—is similarly focused on equity. For ASCO, health equity is not only a theme of its annual...

Approximately 15% of cancer patients in the United States are Black, but only up to 6% of participants in clinical trials are Black. In addition, patients with metastatic breast cancer who are Black often face worse survival rates than other groups of people. So how can this discrepancy be addressed? In this study, published in...

Treatment options for classical Hodgkin lymphoma (cHL) have expanded to the use of multiple chemotherapy drugs that have increased 5-year survival rates to approximately 90%. However, 20-30% of treated patients will experience progression or relapse of the disease at some point after treatment [1]. Disease progression or relapse is often dealt with through the use...

Photo by © ASCO/Nick Agro 2022. Written and edited by Lauren Weinand, M.D.  Two groundbreaking studies presented at the 2022 ASCO Annual Meeting discussed the use of brentuximab vedotin to treat classical Hodgkin lymphoma (CHL) in adults as well as children and adolescents. Here are some of the highlights, including MD Newsline’s Q&A session with...

The conventional treatment modality for stage III or IV Hodgkin lymphoma has been doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), which has remained unmodified over the years. However, a significant percentage of patients experience relapse or refractory disease after treatment with ABVD. New treatment methods, namely treatment regimens with brentuximab vedotin, have proven to be relatively...